Prelude Capital Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-7,239
Closed -$389K 1991
2021
Q1
$389K Buy
7,239
+1,103
+18% +$63.5K 0.01% 1017
2020
Q4
$300K Buy
+6,136
New +$284K 0.01% 914
2019
Q4
Sell
-80,549
Closed -$1.93M 2273
2019
Q3
$1.93M Sell
80,549
-3,361
-4% -$89.4K 0.09% 192
2019
Q2
$2.39M Sell
83,910
-114,865
-58% -$2.87M 0.12% 157
2019
Q1
$4.97M Sell
198,775
-44,799
-18% -$855K 0.28% 64
2018
Q4
$3.06M Buy
243,574
+94,249
+63% +$1.11M 0.21% 101
2018
Q3
$1.43M Sell
149,325
-31,465
-17% -$347K 0.08% 276
2018
Q2
$1.69M Buy
180,790
+51,135
+39% +$360K 0.11% 203
2018
Q1
$721K Buy
129,655
+92,539
+249% +$573K 0.05% 357
2017
Q4
$242K Buy
37,116
+15,316
+70% +$114K 0.02% 575
2017
Q3
$191K Buy
+21,800
New +$177K 0.02% 669
2017
Q2
Sell
-63,397
Closed -$582K 1876
2017
Q1
$582K Buy
+63,397
New +$519K 0.06% 321

Other funds holding VCYT

Prelude Capital Management's VCYT Position: Q2 2021 in Review

Prelude Capital Management sold out of Veracyte (VCYT) in Q2 2021, closing a stake of 7,239 shares — an estimated $389K sold.

Prelude Capital Management first reported a position in VCYT in Q1 2017 and held it in 12 quarters. The position peaked at $4.97M in Q1 2019. 214 funds tracked by Wall St. Rank hold VCYT as of Q2 2021.

  • Prelude Capital Management reported no remaining Veracyte position as of Q2 2021 after selling out during the quarter.
  • Prelude Capital Management sold 7,239 Veracyte shares in Q2 2021, an estimated $389K.
  • Prelude Capital Management first reported a position in Veracyte in Q1 2017 and held it in 12 quarters.
  • Prelude Capital Management's Veracyte position peaked at $4.97M in Q1 2019.
  • 214 funds tracked by Wall St. Rank held Veracyte as of Q2 2021.

Based on Prelude Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.